<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03820986</url>
  </required_header>
  <id_info>
    <org_study_id>7902-003</org_study_id>
    <secondary_id>2018-002520-16</secondary_id>
    <secondary_id>MK-7902-003</secondary_id>
    <secondary_id>E7080-G000-312</secondary_id>
    <secondary_id>LEAP-003</secondary_id>
    <nct_id>NCT03820986</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)</brief_title>
  <official_title>A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants With Advanced Melanoma (LEAP-003)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475)
      combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for
      lenvatinib) as first-line treatment in adults with no prior systemic therapy for their
      advanced melanoma.

      The primary study hypotheses are that: 1) The combination of pembrolizumab and lenvatinib is
      superior to pembrolizumab and placebo as assessed by Progression-free Survival (PFS) per
      Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), and 2) The combination
      of pembrolizumab and lenvatinib is superior to pembrolizumab and placebo as assessed by
      Overall Survival (OS). For this study, RECIST 1.1 has been modified to follow a maximum of 10
      target lesions and a maximum of 5 target lesions per organ.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Anticipated">April 6, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 6, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>PFS is defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. PFS as assessed by modified RECIST 1.1 will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>OS is defined as the time from date of randomization to date of death from any cause. OS will be presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) as Assessed by Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. ORR as assessed by modified RECIST 1.1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as Assessed by Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the date of the first documented evidence of CR or PR until PD or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. DOR as assessed by modified RECIST 1.1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 28 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] Global Health Status (GHS) Score</measure>
    <time_frame>Baseline (Cycle 1 Day 1: Predose) and at designated time points: Predose; each cycle is 21 days (Up to approximately 2 years)</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The GHS Score consists of participant responses to questions regarding GHS (How would you rate your overall health during the past week?). For GHS, responses range in score from 0 to 100, with a higher score indicating a better outcome. The change from Baseline in GHS Score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] Physical Function (PF) Score</measure>
    <time_frame>Baseline (Cycle 1 Day 1: Predose) and at designated time points: Predose; each cycle is 21 days (Up to approximately 2 years)</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The PF Score consists of participant responses to questions regarding PF (5 questions about daily activities [strenuous activities, long walks, short walks, bed/chair rest and needing help with eating, dressing, washing themselves or using the toilet]. For PF, responses range in score from 0 to 100, with a higher score indicating a better outcome. The change from Baseline in PF Score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to True Deterioration (TTD) Based on Change from Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] in Global Health Status (GHS) Score</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>TTD is defined as the time from Baseline to 1st onset of a ≥10-point negative change (decrease) in EORTC-QLQ-C30 GHS Score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The GHS Score consists of participant responses to questions regarding GHS (How would you rate your overall health during the past week?). For GHS, responses range in score from 0 to 100, with a higher score indicating a better outcome. TTD, based on a ≥10-point negative change (decrease) from Baseline in GHS Score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to True Deterioration (TTD) Based on Change from Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] in Physical Function (PF) Score</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>TTD is defined as the time from Baseline to 1st onset of a ≥10-point negative change (decrease) in EORTC-QLQ-C30 PF Score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The PF Score consists of participant responses to questions regarding PF (5 questions about daily activities [strenuous activities, long walks, short walks, bed/chair rest &amp; needing help with eating, dressing, washing themselves or using the toilet]. For PF, responses range in score from 0 to 100, with a higher score indicating a better outcome. TTD, based on a ≥10-point negative change (decrease) from Baseline in PF Score will be presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+Lenvatinib</arm_group_label>
    <arm_group_label>Pembrolizumab+Placebo</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Pembrolizumab+Lenvatinib</arm_group_label>
    <other_name>MK-7902</other_name>
    <other_name>E7080</other_name>
    <other_name>LENVIMA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for lenvatinib</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Pembrolizumab+Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has histologically or cytologically confirmed melanoma

          -  Has unresectable Stage III or Stage IV melanoma, as per American Joint Committee on
             Cancer guidelines, not amenable to local therapy

          -  Has been untreated for advanced or metastatic disease except as follows: a.
             proto-oncogene B-Raf (BRAF) V600 mutation-positive melanoma may have received standard
             of care targeted therapy as first-line therapy for advanced or metastatic disease. b.
             Prior adjuvant or neoadjuvant therapy, with targeted therapy or immunotherapy (such as
             anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], anti-programmed cell death
             1 [anti-PD-1] therapy or Interferon) will only be permitted if relapse did not occur
             during active treatment or within 6 months of treatment discontinuation.

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

          -  Has the presence of ≥1 measurable lesion by computed tomography (CT) or magnetic
             resonance imaging (MRI) per RECIST 1.1

          -  Provides a tumor biopsy. Participants must submit tumor sample during Screening for
             confirmation of adequacy of tumor tissue at a central pathology laboratory.
             Participants who do not submit a tumor tissue sample will not be randomized. The tumor
             biopsy may not be obtained from a lone target lesion. Confirmation of presence of
             tumor tissue is not required prior to randomization.

          -  Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less
             (except alopecia). If participant received major surgery or radiation therapy of &gt;30
             Gray (Gy), they must have recovered from the toxicity and/or complications from the
             intervention.

          -  Male participants must agree to use contraception during the treatment period and for
             at least 120 days after the last dose of study treatment and refrain from donating
             sperm during this period

          -  Female participants must not be pregnant, not breastfeeding, and ≥1 of the following
             conditions applies: a. Not a woman of childbearing potential (WOCBP) OR b. A WOCBP who
             agrees to use study-approved contraception during the treatment period and for at
             least 120 days after the last dose of study treatment

          -  Has adequately controlled blood pressure (BP) with or without antihypertensive
             medications, defined as BP ≤150/90 mmHg at screening and no change in antihypertensive
             medications within 1 week before Cycle 1 Day 1

          -  Has adequate organ function

        Exclusion Criteria:

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days before the first dose of study treatment.

          -  Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include early stage cancers (carcinoma in situ or Stage 1, non-ulcerated
             primary melanoma &lt;1 mm in depth with no nodal involvement) treated with curative
             intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ
             cervical cancer, or in situ breast cancer that has undergone potentially curative
             therapy.

          -  Has known active central nervous system metastases and/or carcinomatous meningitis

          -  Has ocular melanoma

          -  Has known hypersensitivity to active substances or any of their excipients including
             previous clinically significant hypersensitivity reaction to treatment with another
             monoclonal antibody

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years
             (i.e., with use of disease-modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

          -  Has an active infection requiring systemic therapy

          -  Has known history of human immunodeficiency virus (HIV) infection

          -  Has known history of or is positive for hepatitis B virus or hepatitis C virus
             infection

          -  Has a history of (non-infectious) pneumonitis that required steroids or current
             pneumonitis

          -  Has a history of active tuberculosis (Bacillus tuberculosis)

          -  Has presence of gastrointestinal condition including malabsorption, gastrointestinal
             anastomosis, or any other condition that might affect the absorption of lenvatinib

          -  Has had a major surgery within 4 weeks prior to Cycle 1 Day 1. Adequate wound healing
             after major surgery must be assessed clinically and have resolved completely prior to
             Cycle 1 Day 1.

          -  Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula

          -  Has radiographic evidence of major blood vessel invasion/infiltration

          -  Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the
             first dose of study treatment

          -  Has clinically significant cardiovascular disease within 12 months of the first dose
             of study treatment including New York Heart Association Class III or IV congestive
             heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or
             cardiac arrhythmia associated with hemodynamic instability

          -  Has received prior systemic treatment for unresectable or metastatic melanoma other
             than targeted therapy as noted in Inclusion Criteria above

          -  Has received prior therapy with a monoclonal antibody, chemotherapy, or an
             investigational agent or device within 4 weeks or 5 half-lives (whichever is longer)
             before administration of study treatment or not recovered (≤Grade 1 or at Baseline)
             from adverse events due to previously administered agents.

        Exception to this rule would be use of denosumab, which is not excluded. Note: Participants
        with alopecia and ≤Grade 2 neuropathy are an exception and may enroll.

          -  Has received prior radiotherapy within 2 weeks of first dose of study treatment (Cycle
             1 Day 1). Participants must have recovered from all radiation-related toxicities, not
             require corticosteroids, and not have had radiation pneumonitis.

          -  Has received live vaccine within 30 days before the first dose of study treatment

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study treatment

          -  Has had an allogeneic tissue/solid organ transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute ( Site 0707)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-231-2181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute ( Site 0705)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-600-3472</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0704)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>813-745-8581</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute ( Site 0706)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-582-7455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center ( Site 0708)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-848-7135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center ( Site 0709)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-737-5381</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMG Oncology ( Site 0714)</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>847-410-0658</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care, PC ( Site 0765)</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>309-243-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Specialist, PA ( Site 0766)</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>763-786-1620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center ( Site 0724)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>406-238-6290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Cancer Hospital ( Site 0751)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>28512</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>OHSU Center for Health &amp; Healing ( Site 0731)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503-494-1080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute ( Site 0739)</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031-4867</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>571-472-0237</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lismore Base Hospital ( Site 0453)</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61266202416</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia ( Site 0452)</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61299117321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital ( Site 0451)</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61298458543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital ( Site 0454)</name>
      <address>
        <city>Wooloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61731767825</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Health ( Site 0457)</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61398953281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital ( Site 0456)</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61861526530</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PERSONAL - Oncologia de Precisao e Personalizada ( Site 0399)</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+553136576864</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Caridade de Ijui ( Site 0391)</name>
      <address>
        <city>Ijui</city>
        <state>Rio Grande Do Sul</state>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555533319393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Vicente de Paulo ( Site 0396)</name>
      <address>
        <city>Passo Fundo</city>
        <state>Rio Grande Do Sul</state>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555421034130</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0397)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555133203039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancer Hospital do Cancer II ( Site 0394)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20220-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+552122764964</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0661)</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>2507123966686740</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lions Gate Hospital ( Site 0662)</name>
      <address>
        <city>North Vancouver</city>
        <state>British Columbia</state>
        <zip>V7L 2L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute ( Site 0654)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4164804662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0652)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514890800013680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre ( Site 0651)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514934193435033</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Oncologico del Sur ( Site 0425)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56995579412</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez FALP ( Site 0421)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>7500921</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5624205100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile ( Site 0422)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56996898431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedad Medica Aren y Bachero Limitada ( Site 0426)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56954240723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncocentro ( Site 0424)</name>
      <address>
        <city>Vina del Mar</city>
        <state>Valparaiso</state>
        <zip>2520598</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992369820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital ( Site 0601)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+861088196391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital ( Site 0605)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310018</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8613605716662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital ARCHET 2 ( Site 0009)</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33492036223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Timone ( Site 0002)</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhone</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33491388801</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne ( Site 0010)</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d'Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33380293336</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud IUCT Oncopole ( Site 0003)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33531155812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Ambroise Pare Boulogne ( Site 0007)</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <state>Hauts-de-Seine</state>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33149095771</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hopital Claude Huriez ( Site 0004)</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320444193</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen ( Site 0013)</name>
      <address>
        <city>Rouen</city>
        <state>Seine-Maritime</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33232888141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy ( Site 0012)</name>
      <address>
        <city>Argenteuil</city>
        <state>Val-d'Oise</state>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33134231445</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy ( Site 0001)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142114210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de la Miletrie Poitiers ( Site 0011)</name>
      <address>
        <city>Poitiers</city>
        <state>Vienne</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33549444459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg ( Site 0036)</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4993120126779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hautkrebszentrum Buxtehude ( Site 0037)</name>
      <address>
        <city>Buxtehude</city>
        <state>Niedersachsen</state>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4941617036250</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik fur Dermatologie Allergologie und Venerologie ( Site 0035)</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4951192460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus ( Site 0041)</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4935145819782</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig ( Site 0040)</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493419718600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein Campus Kiel ( Site 0033)</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4943150021131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center ( Site 0303)</name>
      <address>
        <city>Beer Sheva</city>
        <state>HaDarom</state>
        <zip>8457108</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97286400797</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0302)</name>
      <address>
        <city>Petah Tikva</city>
        <state>HaMerkaz</state>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239378016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shamir Medical Center-Assaf Harofeh ( Site 0308)</name>
      <address>
        <city>Zerifin</city>
        <state>HaMerkaz</state>
        <zip>7030001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97289779715</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HaEmek Medical Center ( Site 0306)</name>
      <address>
        <city>Afula</city>
        <state>HaTsafon</state>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97246495723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0301)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97248543811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 0304)</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tell Abib</state>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235302243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 0307)</name>
      <address>
        <city>Tel Aviv</city>
        <state>Tell Abib</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236974907</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Hebrew University Medical Center ( Site 0305)</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226776781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII ( Site 0062)</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390352673687</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0064)</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223902557</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia ( Site 0067)</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390257489459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione Pascale ( Site 0061)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390815903236</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto ( Site 0063)</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390498215931</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese ( Site 0065)</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390577586303</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital ( Site 0553)</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82532003017</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 0554)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220722216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0552)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222288137</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0551)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230101779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruna. CHUAC ( Site 0182)</name>
      <address>
        <city>A Coruna</city>
        <state>A Coruna [La Coruna]</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34981178000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial Barcelona ( Site 0190)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932275402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reinals ICO de Hospitalet ( Site 0187)</name>
      <address>
        <city>Hospitalet del Llobregat</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932607333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla ( Site 0181)</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34942202525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran Canaria ( Site 0189)</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34928444000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon ( Site 0191)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914269394</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal ( Site 0183)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0184)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34912071138</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Carlos Haya ( Site 0186)</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34951291425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laenssjukhuset Ryhov ( Site 0215)</name>
      <address>
        <city>Jonkoping</city>
        <state>Jonkopings Lan [se-06]</state>
        <zip>551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46101032962</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrallasarettet Vaxjo ( Site 0214)</name>
      <address>
        <city>Vaxjo</city>
        <state>Kronobergs Lan [se-07]</state>
        <zip>351 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46470588000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus ( Site 0213)</name>
      <address>
        <city>Lund</city>
        <state>Skane Lan [se-12]</state>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4646177520</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset ( Site 0211)</name>
      <address>
        <city>Solna</city>
        <state>Stockholms Lan [se-01]</state>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46851770000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset ( Site 0218)</name>
      <address>
        <city>Uppsala</city>
        <state>Uppsala Lan [se-03]</state>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46186110000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus ( Site 0216)</name>
      <address>
        <city>Umea</city>
        <state>Vasterbottens Lan [se-24]</state>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46907851993</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset ( Site 0212)</name>
      <address>
        <city>Goteborg</city>
        <state>Vastra Gotalands Lan [se-14]</state>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46313428801</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel ( Site 0094)</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4021</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41612655074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden ( Site 0091)</name>
      <address>
        <city>Chur</city>
        <state>Grisons</state>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41812566646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur ( Site 0095)</name>
      <address>
        <city>Winterthur</city>
        <state>Zurich</state>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41522663065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zuerich ( Site 0092)</name>
      <address>
        <city>Zuerich</city>
        <state>Zurich</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41442552588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western General Hospital ( Site 0121)</name>
      <address>
        <city>Edinburgh</city>
        <state>Edinburgh, City Of</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441315373035</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas NHS Foundation Trust ( Site 0126)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442071884244</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital ( Site 0129)</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441752431957</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital ( Site 0131)</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441792285299</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trial Information</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>programmed cell death 1 (PD-1, PD1)</keyword>
  <keyword>programmed cell death-ligand 1 (PD-L1, PDL1)</keyword>
  <keyword>programmed cell death-ligand 2 (PD-L2, PDL2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

